Cannabis Use Was Linked to 2.5x Higher 30-Day Hospital Readmission for Ulcerative Colitis but Not Crohn's Disease
Among 1,021 IBD patients, pre-admission cannabis use was associated with 2.5-fold higher odds of 30-day readmission for ulcerative colitis but not Crohn's disease.
Quick Facts
What This Study Found
Of 1,021 IBD admissions, 7.25% reported cannabis use. Cannabis was associated with 30-day readmission in UC (OR 2.48) but not CD (OR 0.59). No association with 90-day readmission (OR 1.19).
Key Numbers
1,021 admissions. 74 (7.25%) reported cannabis. UC 30-day readmission OR: 2.48. CD OR: 0.59. 90-day OR: 1.19 (not significant).
How They Did This
Retrospective review of adults admitted for IBD exacerbation from 2016-2020 within Northwell Health. Cannabis identified through admission document text search.
Why This Research Matters
Many IBD patients use cannabis for symptom relief. This study suggests cannabis may be associated with worse short-term outcomes specifically in ulcerative colitis.
The Bigger Picture
The divergent findings between UC and Crohn's suggest cannabis may interact differently with different IBD subtypes.
What This Study Doesn't Tell Us
Retrospective. Text-based cannabis identification likely underestimates. Few cannabis users (74). Cannot determine dose or frequency.
Questions This Raises
- ?Why might cannabis use be associated with readmission in UC but not Crohn's?
- ?Does cannabis form or dose matter for IBD outcomes?
Trust & Context
- Key Stat:
- 2.5x higher 30-day readmission for cannabis-using UC patients
- Evidence Grade:
- Retrospective cohort with multivariable adjustment, limited by small cannabis user count.
- Study Age:
- Published 2023, using 2016-2020 data.
- Original Title:
- Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation.
- Published In:
- Journal of clinical medicine research, 15(2), 99-108 (2023)
- Authors:
- Oseni, Ellen A, Blumenthal, Miriam, Izard, Stephanie, Qiu, Michael, Mone, Anjali, Swaminath, Arun, Sultan, Keith
- Database ID:
- RTHC-04828
Evidence Hierarchy
Looks back at existing records to find patterns.
What do these levels mean? →Frequently Asked Questions
Does cannabis affect IBD hospital outcomes?
Cannabis use was associated with 2.5x higher 30-day readmission for ulcerative colitis but not Crohn's disease.
How common is cannabis use among IBD patients?
7.25% of hospitalized IBD patients reported cannabis use, likely an underestimate.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04828APA
Oseni, Ellen A; Blumenthal, Miriam; Izard, Stephanie; Qiu, Michael; Mone, Anjali; Swaminath, Arun; Sultan, Keith. (2023). Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation.. Journal of clinical medicine research, 15(2), 99-108. https://doi.org/10.14740/jocmr4846
MLA
Oseni, Ellen A, et al. "Cannabis Use and Its Association With Thirty- and Ninety-Day Hospital Readmissions for Patients Admitted for an Inflammatory Bowel Disease Exacerbation.." Journal of clinical medicine research, 2023. https://doi.org/10.14740/jocmr4846
RethinkTHC
RethinkTHC Research Database. "Cannabis Use and Its Association With Thirty- and Ninety-Day..." RTHC-04828. Retrieved from https://rethinkthc.com/research/oseni-2023-cannabis-use-and-its
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.